Francesco Gaudio, Giacomo Loseto, Valentina Bozzoli, Potito Rosario Scalzulli, Anna Maria Mazzone, Lorenzo Tonialini, Vincenza Fesce, Giovanni Quintana, Gaetano De Santis, Pierluigi Masciopinto, Elena Arcuti, Felice Clemente, Stefania Scardino, Giuseppe Tarantini, Domenico Pastore, Lorella Melillo, Vincenzo Pavone, Alessandro Maggi, Angelo Michele Carella, Nicola Di Renzo, Attilio Guarini, Pellegrino Musto
Checkpoint inhibitors have significantly changed the prognosis of patients with relapsing refractory classical Hodgkin's lymphoma (cHL), demonstrating excellent results in heavily pretreated patients. However, there is still limited data on the real-world experience with PD-1 inhibitors in cHL. Within the context of the Apulian hematological network (Rete Ematologica Pugliese, REP), we performed a retrospective, multicenter analysis of 66 patients with relapsing refractory cHL who had received PD-1 inhibitors in the non-trial setting...
January 16, 2023: Annals of Hematology